Header

Newsroom

Ad-hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

View Featured news and Pulse updates.

Showing 21 results

January 2025

Pulse Update Jan 14, 2025
Novartis presentation at J.P. Morgan Healthcare Conference 2025

December 2024

Pulse Update Dec 02, 2024
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease

May 2024

Pulse Update May 10, 2024
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML

April 2024

February 2024

Pulse Update Feb 16, 2024
Novartis appoints Sloan Simpson as Global Head of Investor Relations

January 2024

Pulse Update Jan 08, 2024
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024

April 2023

Pulse Update Apr 21, 2023
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®

March 2023

Pulse Update Mar 02, 2023
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch

January 2023

Pulse Update Jan 09, 2023
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023

December 2021

Pulse Update Dec 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

September 2021

Pulse Update Sep 28, 2021
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)

AddToAny buttons

Share Post Share Whatsapp Linkedin Email

Printable Links Block (Content)